BioAtla, Inc. BCAB 深 滬
等待開盤 12-16 09:30:00 美东时间
0.7885
-0.036
-4.35%
華盛通- 最 高0.8793
- 今 開0.8221
- 成交量 102.08万股
- 最 低 0.7437
- 昨 收 0.8244
- 總市值 4635.76万
- 52周最高 1.43
- 市盈率 靜 --
- 換手率 1.74%
- 52周最低 0.24
- 委 比 -80.00%
- 總股本 5879.21万
- 歷史最高 76.63
- 量 比 1.39
- 振 幅 16.45%
- 歷史最低 0.24
- 每 手 1
- 風險率 0.23%
個股概要
財務分析
公司資料
相關新聞
分紅派息
- 分時圖
- 日k
- 周k
- 月k
相關新聞
更多BioAtla Secures $7.5 Million Pre-Paid Advance
BioAtla ( ($BCAB) ) has issued an update. On November 20, 2025, BioAtla, Inc. e...
11-21 19:43
BioAtla Secures $7.5M Advance And Up To $15M Standby Equity Commitment To Support Strategic Transaction
These agreements are designed to be a flexible financing solution to support operations while finalizing a strategic partnershipCompany is in advanced stages to finalize a strategic transaction with a potential partner,
11-21 15:44
12 Health Care Stocks Moving In Tuesday's After-Market Session
Gainers enGene Holdings (NASDAQ:ENGN) stock moved upwards by 3.5% to $7.12 dur...
11-19 05:06
Earnings Scheduled For November 13, 2025
Companies Reporting Before The Bell • Edgewell Personal Care (NYSE:EPC) is proj...
11-13 19:11
What's Next: BioAtla's Earnings Preview
BioAtla (NASDAQ:BCAB) is set to give its latest quarterly earnings report on Th...
11-13 00:03
BioAtla Presents Clinical Data In Poster Titled "Median OS Of 21.5 Months Among 44 Patients With Treatment-Refractory Leiomyosarcoma, Liposarcoma, And Undifferentiated Pleomorphic Sarcoma Treated With Mecbotamab Vedotin, An AXL-Targeting ADC," At SITC 2025
— Mec-V demonstrates median OS of 21.5 months in patients with treatment-refractory leiomyosarcoma, liposarcoma, and undifferentiated pleomorphic sarcoma compared with approximately 12 months with approved agents— Mec-V
11-07 22:12
BioAtla Presents Compelling Mechanistic Rationale for Targeting ROR2 with Ozuriftamab Vedotin (Oz-V) in Oropharyngeal Squamous Cell Carcinoma (OPSCC) at the Annual Conference of the International Papillomavirus Society
BioAtla presents clinical data on Ozuriftamab Vedotin (Oz-V), a novel antibody-drug conjugate targeting ROR2 in HPV+ oropharyngeal cancer, at the IPVS Conference in Bangkok. The poster highlights Oz-V's mechanism, clinical results showing an overall response rate of 45%, and plans for a Phase 3 trial in early 2026. OPSCC, driven by HPV, is a significant and underserved cancer population with poor prognosis. Oz-V has received FDA Fast Track Design...
10-23 12:00
BioAtla Presents Promising Interim Data from its Phase 1 Trial with BA3182 in Patients with Treatment Refractory Metastatic Adenocarcinoma at ESMO 2025
BioAtla, Inc. announced preliminary results from a Phase 1 study of BA3182, a dual-conditional binding bispecific T-cell engager targeting EpCAM and CD3, designed to selectively bind in acidic tumor microenvironments to minimize off-tumor toxicity. The study demonstrated manageable safety, with transient adverse events and minimal cytokine release syndrome (CRS). Efficacy showed prolonged tumor control, including a confirmed partial response (cPR...
10-20 12:00
12 Health Care Stocks Moving In Tuesday's Intraday Session
Gainers Strata Skin Sciences (NASDAQ:SSKN) shares increased by 44.9% to $2.23 ...
10-15 01:06
BioAtla Will Present Clinical Data For Its Investigational Axl-Targeting Antibody-Drug Conjugate Mecbotamab Vedotin At The SITC 2025 Annual Meeting
BioAtla, Inc. (NASDAQ:BCAB), a global clinical-stage biotechnology company focused on the development of Conditionally Active Biologic (CAB) antibody therapeutics using its proprietary CAB platform for the treatment of
10-03 21:03
